BIOVIC B Stock Overview
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Biovica International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.37 |
| 52 Week High | kr10.36 |
| 52 Week Low | kr1.85 |
| Beta | 1.21 |
| 1 Month Change | 2.83% |
| 3 Month Change | -14.31% |
| 1 Year Change | -71.16% |
| 3 Year Change | -93.91% |
| 5 Year Change | -78.40% |
| Change since IPO | -80.21% |
Recent News & Updates
Recent updates
Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?
Jul 18
Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 02Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation
Aug 02Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Feb 17A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)
Jan 19Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth
Nov 11We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth
Aug 06We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn
Mar 20Who Has Been Buying Biovica International AB (publ) (STO:BIOVIC B) Shares?
Feb 22What Kind Of Shareholders Hold The Majority In Biovica International AB (publ)'s (STO:BIOVIC B) Shares?
Jan 26The Biovica International (STO:BIOVIC B) Share Price Has Soared 349%, Delighting Many Shareholders
Dec 31
Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 05Shareholder Returns
| BIOVIC B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 7.5% | -1.0% | -1.7% |
| 1Y | -71.2% | -6.3% | 8.1% |
Return vs Industry: BIOVIC B underperformed the Swedish Biotechs industry which returned -6.3% over the past year.
Return vs Market: BIOVIC B underperformed the Swedish Market which returned 8.1% over the past year.
Price Volatility
| BIOVIC B volatility | |
|---|---|
| BIOVIC B Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: BIOVIC B has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOVIC B's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 37 | Anders Rylander | www.biovica.com |
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a biomarker assay that measures thymidine kinase activity, which reflects tumor cell proliferation.
Biovica International AB (publ) Fundamentals Summary
| BIOVIC B fundamental statistics | |
|---|---|
| Market cap | kr198.79m |
| Earnings (TTM) | -kr122.99m |
| Revenue (TTM) | kr6.97m |
28.5x
P/S Ratio-1.6x
P/E RatioIs BIOVIC B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOVIC B income statement (TTM) | |
|---|---|
| Revenue | kr6.97m |
| Cost of Revenue | -kr483.00k |
| Gross Profit | kr7.45m |
| Other Expenses | kr130.44m |
| Earnings | -kr122.99m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
Jun 18, 2024
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 106.93% |
| Net Profit Margin | -1,765.84% |
| Debt/Equity Ratio | 0% |
How did BIOVIC B perform over the long term?
See historical performance and comparison